Thyroid eye disease
TED · Rare Disease · 2 drugs · 2 indications
Autoimmune eye disease associated with Graves' disease.
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Vyvgart | ARGX | FcRn Inhibitor | Antibody | IV / SC | APPROVED |
| Tepezza | AMGN, GMAB | IGF-1R inhibitor | Antibody | IV | APPROVED |
Indications (2)
Upcoming Catalysts
Vyvgart - Ocular MG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL
ARGXQ1 2026
Vyvgart - oMG - Ph3 - Topline (ADAPT-OCULUS)CLINICAL
ARGX1Q26
Vyvgart - Myositis - Ph2/3 - Topline (ALKIVIA)CLINICAL
ARGXQ3 2026
Vyvgart - ITP - Ph3 - Topline (ADVANCE-NEXT)CLINICAL
ARGXQ4 2026
Vyvgart - AChR- gMG (Seronegative) - FDA Approval DecisionREGULATORY
ARGXBy end of 2026
Vyvgart - Sjogren's Disease - Ph3 - ToplineCLINICAL
ARGXH2 2027
Data from Supabase · Updated 2026-03-24